Reed Jobs, son of the late Steve Jobs, is busy building new biotech companies in oncology instead of discussing his famous last name. His venture firm, Yosemite, launched in 2023 with a mission to innovate cancer cures from university labs.

The firm has already seen success with Azalea and Quarry, while also benefiting from AI advancements in drug discovery. Jobs sees the future of medicine as reliant on early philanthropic investment and collaboration between academia and industry.

Despite initial concerns about conservative biotech investors, interest rates are improving and pharma companies are poised for a significant acquisition period due to patent expirations. Yosemite has managed to secure significant funding and is optimistic about its role in pioneering new areas of medicine.

In a reflective moment, Jobs also discusses the ongoing pressure on NIH budgets, advocating for increased funding as critical infrastructure for medical advancements.